[{"id":"c2b67cc7-ce2b-4a17-af77-efced8e1526f","acronym":"E1609","url":"https://clinicaltrials.gov/study/NCT01274338","created_at":"2023-04-12T19:03:03.311Z","updated_at":"2025-02-25T16:36:09.391Z","phase":"Phase 3","brief_title":"Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery","source_id_and_acronym":"NCT01274338 - E1609","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IFNA1","pipe":"","alterations":" ","tags":["IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • Intron A (interferon α-2b)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1673","initiation":"Initiation: 05/25/2011","start_date":" 05/25/2011","primary_txt":" Primary completion: 02/15/2019","primary_completion_date":" 02/15/2019","study_txt":" Completion: 03/07/2025","study_completion_date":" 03/07/2025","last_update_posted":"2025-02-06"},{"id":"5351b2fd-adc5-41e4-92bd-076122f48c07","acronym":"BRI-ROL-001","url":"https://clinicaltrials.gov/study/NCT03328026","created_at":"2021-01-18T16:26:04.427Z","updated_at":"2025-02-25T16:52:02.280Z","phase":"Phase 1/2","brief_title":"Combination Study of SV-BR-1-GM With Retifanlimab","source_id_and_acronym":"NCT03328026 - BRI-ROL-001","lead_sponsor":"BriaCell Therapeutics Corporation","biomarkers":" ER • PIK3CA • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • PGR positive","tags":["ER • PIK3CA • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Zynyz (retifanlimab-dlwr) • epacadostat (INCB024360) • Bria-IMT (SV-BR-1-GM) • Intron A (interferon α-2b) • cyclophosphamide intravenous"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 36","initiation":"Initiation: 03/16/2018","start_date":" 03/16/2018","primary_txt":" Primary completion: 11/03/2025","primary_completion_date":" 11/03/2025","study_txt":" Completion: 11/30/2028","study_completion_date":" 11/30/2028","last_update_posted":"2025-02-04"},{"id":"15e7f739-98b7-4cb1-a7f5-0dfc757321cf","acronym":"NCI-2020-01520","url":"https://clinicaltrials.gov/study/NCT04348747","created_at":"2021-01-18T21:02:18.854Z","updated_at":"2024-07-02T16:34:26.116Z","phase":"Phase 2","brief_title":"Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer","source_id_and_acronym":"NCT04348747 - NCI-2020-01520","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" PD-L1 • ER • PGR","pipe":" | ","alterations":" PD-L1 expression • HER-2 positive • HER-2 negative","tags":["PD-L1 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Intron A (interferon α-2b) • Ampligen (rintatolimod) • celecoxib oral"],"overall_status":"Recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 12/19/2022","start_date":" 12/19/2022","primary_txt":" Primary completion: 06/15/2025","primary_completion_date":" 06/15/2025","study_txt":" Completion: 12/15/2026","study_completion_date":" 12/15/2026","last_update_posted":"2024-06-14"},{"id":"8e13ae6f-2afc-43dc-b06c-933f9e190424","acronym":"","url":"https://clinicaltrials.gov/study/NCT04093323","created_at":"2023-11-30T22:15:48.537Z","updated_at":"2024-07-02T16:35:00.203Z","phase":"Phase 2","brief_title":"Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma","source_id_and_acronym":"NCT04093323","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" CD8","pipe":" | ","alterations":" CD8 positive","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Intron A (interferon α-2b) • Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 06/20/2024","start_date":" 06/20/2024","primary_txt":" Primary completion: 08/22/2025","primary_completion_date":" 08/22/2025","study_txt":" Completion: 08/22/2025","study_completion_date":" 08/22/2025","last_update_posted":"2024-05-30"},{"id":"af5b2b8c-e254-4a25-b607-944acb5d90e8","acronym":"SWOG S1404","url":"https://clinicaltrials.gov/study/NCT02506153","created_at":"2021-01-18T12:05:51.420Z","updated_at":"2024-07-02T16:35:01.870Z","phase":"Phase 3","brief_title":"Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery","source_id_and_acronym":"NCT02506153 - SWOG S1404","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • Intron A (interferon α-2b) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1345","initiation":"Initiation: 11/10/2015","start_date":" 11/10/2015","primary_txt":" Primary completion: 09/15/2023","primary_completion_date":" 09/15/2023","study_txt":" Completion: 01/23/2025","study_completion_date":" 01/23/2025","last_update_posted":"2024-05-22"},{"id":"59bdfa97-7b2e-46bf-97c1-23ab33821d5c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04081389","created_at":"2021-01-18T19:59:01.001Z","updated_at":"2024-07-02T16:35:37.452Z","phase":"Phase 1","brief_title":"Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer","source_id_and_acronym":"NCT04081389","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" PGR","pipe":" | ","alterations":" ER positive + PGR positive • PGR positive","tags":["PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive + PGR positive • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • doxorubicin hydrochloride • cyclophosphamide • daunorubicin • Intron A (interferon α-2b) • Ampligen (rintatolimod) • celecoxib oral • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 12/06/2019","start_date":" 12/06/2019","primary_txt":" Primary completion: 05/24/2022","primary_completion_date":" 05/24/2022","study_txt":" Completion: 02/27/2023","study_completion_date":" 02/27/2023","last_update_posted":"2023-09-11"},{"id":"6b4d4b82-c21b-4836-9065-ad8decf020a2","acronym":"","url":"https://clinicaltrials.gov/study/NCT00062010","created_at":"2021-01-18T00:08:26.426Z","updated_at":"2024-07-02T16:35:43.619Z","phase":"Phase 2","brief_title":"Interferon Alfa, Isotretinoin, and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer","source_id_and_acronym":"NCT00062010","lead_sponsor":"Eastern Cooperative Oncology Group","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Intron A (interferon α-2b)"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 05/26/2004","start_date":" 05/26/2004","primary_txt":" Primary completion: 05/01/2011","primary_completion_date":" 05/01/2011","study_txt":" Completion: 08/01/2012","study_completion_date":" 08/01/2012","last_update_posted":"2023-07-07"},{"id":"112a8f53-b48b-4fcf-ab56-3185a8febfbf","acronym":"","url":"https://clinicaltrials.gov/study/NCT04379518","created_at":"2021-01-18T21:09:01.336Z","updated_at":"2024-07-02T16:35:53.963Z","phase":"Phase 1/2","brief_title":"Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients","source_id_and_acronym":"NCT04379518","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Intron A (interferon α-2b) • Ampligen (rintatolimod)"],"overall_status":"Suspended","enrollment":" Enrollment 64","initiation":"Initiation: 11/17/2020","start_date":" 11/17/2020","primary_txt":" Primary completion: 11/17/2023","primary_completion_date":" 11/17/2023","study_txt":" Completion: 11/17/2023","study_completion_date":" 11/17/2023","last_update_posted":"2023-03-06"},{"id":"2ef799d3-1ede-4380-b63e-812810bb7c1f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03403634","created_at":"2021-01-18T16:47:42.513Z","updated_at":"2024-07-02T16:36:16.175Z","phase":"Phase 2a","brief_title":"Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver","source_id_and_acronym":"NCT03403634","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" PD-L1 • MSI • CD8","pipe":" | ","alterations":" MSI-H/dMMR • RAS wild-type","tags":["PD-L1 • MSI • CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Intron A (interferon α-2b) • Ampligen (rintatolimod) • celecoxib oral"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 04/19/2018","start_date":" 04/19/2018","primary_txt":" Primary completion: 12/23/2020","primary_completion_date":" 12/23/2020","study_txt":" Completion: 08/29/2021","study_completion_date":" 08/29/2021","last_update_posted":"2022-03-02"},{"id":"ea14f1dd-83ae-4642-802b-7e2c102f2e24","acronym":"","url":"https://clinicaltrials.gov/study/NCT00001114","created_at":"2021-01-17T22:44:07.416Z","updated_at":"2025-02-25T14:22:45.692Z","phase":"Phase 2","brief_title":"The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi's Sarcoma","source_id_and_acronym":"NCT00001114","lead_sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","biomarkers":" CD4 • IFNA1","pipe":"","alterations":" ","tags":["CD4 • IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Intron A (interferon α-2b)"],"overall_status":"Completed","enrollment":" Enrollment 90","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":" Completion: 03/01/2000","study_completion_date":" 03/01/2000","last_update_posted":"2021-11-01"},{"id":"d160bba2-646c-4438-b590-5eb0c74d7442","acronym":"","url":"https://clinicaltrials.gov/study/NCT02151448","created_at":"2021-01-18T09:59:55.040Z","updated_at":"2024-07-02T16:36:43.024Z","phase":"Phase 1/2","brief_title":"αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies","source_id_and_acronym":"NCT02151448","lead_sponsor":"David Bartlett","biomarkers":" IL6 • TNFA • CXCL8 • CXCL10 • CXCL12 • IL10 • CXCL11","pipe":" | ","alterations":" IL10 elevation","tags":["IL6 • TNFA • CXCL8 • CXCL10 • CXCL12 • IL10 • CXCL11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IL10 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Intron A (interferon α-2b) • Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral"],"overall_status":"Completed","enrollment":" Enrollment 64","initiation":"Initiation: 07/01/2014","start_date":" 07/01/2014","primary_txt":" Primary completion: 02/18/2019","primary_completion_date":" 02/18/2019","study_txt":" Completion: 02/18/2019","study_completion_date":" 02/18/2019","last_update_posted":"2020-07-20"},{"id":"3e538d16-0aec-4c1f-b4d7-a136a14f96af","acronym":"","url":"https://clinicaltrials.gov/study/NCT01603212","created_at":"2021-01-18T06:51:25.271Z","updated_at":"2024-07-02T16:36:59.411Z","phase":"Phase 1","brief_title":"Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor","source_id_and_acronym":"NCT01603212","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IL2","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib) • Intron A (interferon α-2b) • Proleukin (aldesleukin)"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 07/18/2013","start_date":" 07/18/2013","primary_txt":" Primary completion: 07/05/2017","primary_completion_date":" 07/05/2017","study_txt":" Completion: 07/05/2017","study_completion_date":" 07/05/2017","last_update_posted":"2019-05-21"},{"id":"0efd0c25-4f85-4b9c-90a2-c13131a34a18","acronym":"","url":"https://clinicaltrials.gov/study/NCT00629200","created_at":"2021-01-18T02:20:21.030Z","updated_at":"2024-07-02T16:37:05.321Z","phase":"Phase 1","brief_title":"Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies","source_id_and_acronym":"NCT00629200","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IFNA1","pipe":"","alterations":" ","tags":["IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Intron A (interferon α-2b) • Lenocta (sodium stibogluconate)"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 09/13/2006","start_date":" 09/13/2006","primary_txt":" Primary completion: 02/10/2010","primary_completion_date":" 02/10/2010","study_txt":" Completion: 02/10/2010","study_completion_date":" 02/10/2010","last_update_posted":"2018-11-15"},{"id":"3352753e-aefb-46b9-a859-11eaadd3d587","acronym":"","url":"https://clinicaltrials.gov/study/NCT01460875","created_at":"2021-01-18T06:04:28.765Z","updated_at":"2025-02-25T16:01:59.871Z","phase":"","brief_title":"Recombinant Interferon Alfa-2b in Treating Patients With Melanoma","source_id_and_acronym":"NCT01460875","lead_sponsor":"William Carson","biomarkers":" CD69 • IFNA1","pipe":"","alterations":" ","tags":["CD69 • IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Intron A (interferon α-2b)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 04/22/2008","start_date":" 04/22/2008","primary_txt":" Primary completion: 01/05/2014","primary_completion_date":" 01/05/2014","study_txt":" Completion: 01/05/2014","study_completion_date":" 01/05/2014","last_update_posted":"2018-11-02"},{"id":"69f33d3c-e7f9-433f-be3a-0180a4c484ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT01622933","created_at":"2021-06-22T23:52:48.057Z","updated_at":"2024-07-02T16:37:18.262Z","phase":"Phase 1","brief_title":"Multiple Antigen-Engineered DC Vaccine for Melanoma","source_id_and_acronym":"NCT01622933","lead_sponsor":"Lisa H. Butterfield, Ph.D.","biomarkers":" IFNA1","pipe":"","alterations":" ","tags":["IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Intron A (interferon α-2b)"],"overall_status":"Completed","enrollment":" Enrollment 35","initiation":"Initiation: 06/01/2012","start_date":" 06/01/2012","primary_txt":" Primary completion: 05/01/2016","primary_completion_date":" 05/01/2016","study_txt":" Completion: 08/01/2017","study_completion_date":" 08/01/2017","last_update_posted":"2017-08-31"},{"id":"9ff98ed0-b100-49fd-8e72-92c3280d0736","acronym":"","url":"https://clinicaltrials.gov/study/NCT00006244","created_at":"2021-01-17T23:53:07.256Z","updated_at":"2024-07-02T16:37:20.013Z","phase":"Phase 2","brief_title":"Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma","source_id_and_acronym":"NCT00006244","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e melphalan • Intron A (interferon α-2b) • Proleukin (aldesleukin) • Roferon A (recombinant interferon alfa-2a)"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 02/01/2000","start_date":" 02/01/2000","primary_txt":" Primary completion: 04/01/2016","primary_completion_date":" 04/01/2016","study_txt":" Completion: 04/01/2016","study_completion_date":" 04/01/2016","last_update_posted":"2017-07-12"}]